Trillium Reports Second Quarter 2016 Financial Results

Go back to Trillium Reports Second Quarter 2016 Financial Results

Leerink Partners Reiterates Outperform on Trillium Therapeutics (TRIL)

August 16, 2016 2:04 PM EDT

Leerink Partners reiterated an Outperform rating and $20.00 price target on Trillium Therapeutics (NASDAQ: TRIL) as interest continues to build surrounding CD47 as an anti-cancer target. Private company Tioma Therapeutics announced today that it has raised $86M in Series A venture financing that will be used to... More